Table 3.
Pro‐apoptotic | Anti‐apoptotic | Remodelling/maturation | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Fas | FasL | Par‐4 | PHLDA1 | Caspase‐3 | Ki‐67 | Bcl‐2 | Survivin | MUC1 | SPARC | |
Initial bud | + | + | ++ | ++ | 0 | + | + | ++ | 0 | 0 |
Pseudoglandular | 0 | 0 | + | + | 0 | ++ | + | ++ | ++ | 0 |
Canalicular | 0 | 0 | + | + | 0 | + | 0 | + | ++ | 0 |
Terminal bud | 0 | 0 | 0 | 0 | 0 | + | 0 | + | ++ | 0 |
(++) Strong expression; (+) weak expression; (0) no expression; Fas, Fas cell surface death receptor; FasL, Fas ligand; Par‐4, prostate apoptosis response‐4; PHLDA1, pleckstrin homology‐like domain family A member 1; Bcl‐2, B‐cell CLL/lymphoma 2; MUC1, mucin 1; SPARC, secreted protein acidic and cysteine‐rich.